Get Ready, It’s Coming Next Week! What to Expect at COMPUTEX 2021
26.5.2021 10:36:00 EEST | Business Wire | Press release
COMPUTEX 2021 will be launched from May 31 to June 30. The organizer, the Taiwan External Trade Development Council (TAITRA), will roll out the #COMPUTEXVirtual platform to connect the technology community that breaks geographic limitations. COMPUTEX 2021 will offer an exceptional exhibition experience to attendees with the following highlights.
Highlight #1: Top Speakers Will Address on the Groundbreaking Technologies
COMPUTEX 2021 will kick off with the highly anticipated CEO Keynotes. From May 31 to June 2, key industry executives will discuss topics covering AI, high-performance computing (HPC), and other technology trends. Simon Segars, CEO of Arm, Dr. Lisa Su, President and CEO of AMD, Sanjay Mehrotra, President and CEO of Micron, Charles Liang, Founder, President and CEO of Supermicro, and Kurt Sievers, President and CEO of NXP Semiconductors are among the speaker lineup.
The COMPUTEX Forum on June 2 and 3 will revolve around the theme of "The New Era of Intelligence," focusing on key applications of AI, 5G, IoT, and electric vehicles. The forum will unlock the development of quantum computers and explore the infinite possibilities of future technology applications. The world's leading ICT experts will discuss business strategies and pulse industry trends in the post-pandemic era.
Highlight #2: Virtual Booths Will Showcase the Latest Products
#COMPUTEXVirtual, the all-new smart online platform, will use AI and automation technology to create an exceptional digital journey for users by providing a personalized interactive experience. Visitors will be able to obtain the latest product information in real-time.
Acer will showcase its very latest products and innovations that will be announced at its next@acer Global Press Conference to be held on May 27. It will also showcase solutions from its subsidiaries, including products for smart cities, AI, and enterprise use. ZOTAC, on the other hand, will be revealing a brilliant lineup of innovations, including the ZOTAC GAMING GeForce 3090 AMP Extreme Holo graphics card and the MAGNUS ONE ECM53060C mini PC.
Along with the big corporates, innovative startups are always the core elements to drive COMPUTEX and all the industry moving forward. The Epoch Foundation, committed to building partnerships in the global entrepreneurial community, has created a pavilion titled “Garage+ 46 Must-See Startups” on the #COMPUTEXVirtual platform. The exhibition is divided into three sections: “AI & Big Data,” “Digital Health & EdTech,” and “IoT & Energy.”
Moreover, #COMPUTEXVirtual builds #InnoVEXVirtual as a featured exhibit area to help startups connect with the international community. In addition to French Pavilion, Korean Pavilion, and the Dutch Pavilion, the European Bank for Reconstruction and Development (EBRD) is bringing 18 startups from 7 countries to join InnoVEX for the first time.
Highlight #3: Effective Online Platform Functions Will Synergize Matchmaking Opportunities
To maximize the benefits for exhibitors, #COMPUTEXVirtual will provide multiple effective, timely communication channels for exhibitors and visitors, such as video conferencing, meeting requests and instant messaging. Exhibitors can use AI technology to identify target audiences and promote products. Hyper-Personalized Recommendations will also help increase the matchmaking accuracy and enable companies to seize business opportunities effectively.
Together with the technology giants and disruptive startups, COMPUTEX 2021 is ready to bring the world an all-new digital experience. For more exhibition information, please visit the following:
- #COMPUTEXVirtual Online Exhibition Visitor Registration: https://virtual.computextaipei.com.tw/
- COMPUTEX CEO Keynote and COMPUTEX Forum Registration: https://virtual.computextaipei.com.tw/events/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual:
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX,Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnoVEXVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005459/en/
Contact information
For more updates：
COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website : https://www.innovex.com.tw/
Press Contacts:
Ms. Tessa Lin <tessalin@taitra.org.tw
Ms. Li Chao < lichao@taitra.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom